Jefferies Group acquired 2.29 Million Immunome shares worth $17.6 Million. That's 0.34% of their equity portfolio (50th largest holding). The investor owns 2.29% of the outstanding Immunome stock. The first Immunome trade was made in Q1 2024. Since then Jefferies Group bought shares three more times and sold shares on one occasions. The investor's estimated purchase price is $30.9 Million, resulting in a loss of 43%.